Canagliflozin-induced sex-specific adaptive metabolism in bone

ABSTRACT: Sodium glucose transporter-2 inhibitors (SGLT2i) were designed to increase the excretion of glucose through urine and lower blood glucose levels independent of insulin. Beyond their primary functions, SGLT2i have been observed to induce a wide range of metabolic effects. To understand how SGLT2i-mediated metabolic changes affect skeletal metabolism, six months old genetically diverse UM-HET3 mice were treated with canagliflozin (CANA), a SGLT2i, for 1, 3, and 6 months.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

SUBMITTER: Dr. Thomas A. Neubert   Dr.Shoshana Yakar  

PROVIDER: MSV000094557 | MassIVE | Wed Apr 17 12:00:00 BST 2024

REPOSITORIES: MassIVE